<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340105</url>
  </required_header>
  <id_info>
    <org_study_id>CT11005</org_study_id>
    <nct_id>NCT01340105</nct_id>
  </id_info>
  <brief_title>Effectiveness of Microwave Ablation of Hepatocellular Carcinoma as Compared to Radiofrequency Ablation</brief_title>
  <official_title>Microwave Versus Radiofrequency Ablation for Hepatocellular Carcinoma: a Prospective Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare microwave ablation using the Acculis Microwave Tissue
      Ablation (MTA) System with conventional radiofrequency ablation (RFA) using Covidien cool-tip
      radiofrequency needle in patients with localized unresectabe hepatocelluar carcinoma (HCC).

      The investigators hypothesize that microwave ablation can achieve a better complete ablation
      rate as compared to radiofrerquency ablation.

      A randomized comparative study is performed by randomly assigned participants to microwave
      ablation arm or radiofrequency ablation arm. The efficacy of treatment outcome is assessed by
      the complete tumor ablation rate at 1 month, recurrence rate and survival time of
      participants. Safety of the procedures is also compared between the 2 treatment arms.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2011</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete ablation rate</measure>
    <time_frame>1 month</time_frame>
    <description>Measure by post-ablation Computed Tomography (CT) with reference to alpha-fetoprotein (AFP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality</measure>
    <time_frame>30-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent disease</measure>
    <time_frame>3 year</time_frame>
    <description>It is defined as the imaging detected new lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>3 year</time_frame>
    <description>Overall and disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term liver function</measure>
    <time_frame>3 year</time_frame>
    <description>Monitoring of liver function test result and the occurrance of decompensated cirrhosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related morbidity</measure>
    <time_frame>30-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>30-day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Microwave</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiofrequency</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microwave ablation</intervention_name>
    <description>Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.</description>
    <arm_group_label>Microwave</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.</description>
    <arm_group_label>Radiofrequency</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Unresectable hepatocellular carcinoma (HCC) and tumor amendable for local ablation

          -  Resectable HCC but patient opts for local ablation

          -  Maximum diameter of tumor ≤6cm

          -  Maximum number of tumor nodules ≤3

          -  Absence of radiology evidence of major vascular or bile duct invasion

          -  Child's A or B liver function

          -  Karnofsky performance status ≥70%

        Exclusion Criteria:

          -  Informed consent not available

          -  Pregnant female patients

          -  Tumors unfavourable for local ablation (e.g. tumor close to porta hepatis)

          -  HCC with history of rupture

          -  Concomitant hepatectomy

          -  Patients with chronic renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kit-fai Lee, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hepato-biliary and Pancreatic Surgery, Department of Surgery, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kit-fai Lee, MBBS</last_name>
    <phone>(852) 26321411</phone>
    <email>leekf@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kit-fai Lee, MBBS</last_name>
      <phone>(852) 26321411</phone>
      <email>leekf@surgery.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Kit-fai Lee, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2011</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Cheung Yue Sun</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <keyword>Microwave ablation</keyword>
  <keyword>Radiofrequency ablation</keyword>
  <keyword>Randomised controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

